Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models
暂无分享,去创建一个
Francisco Salavert | Joaquín Dopazo | Ignacio Medina | José Carbonell | Marta R. Hidalgo | Marta R. Hidalgo | Cankut Çubuk | Daniel Crespo | Alicia Amadoz | J. Dopazo | I. Medina | A. Amadoz | C. Çubuk | Daniel Crespo | J. Carbonell | F. Salavert | Ignacio Medina
[1] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[2] Joaquín Dopazo,et al. Understanding disease mechanisms with models of signaling pathway activities , 2014, BMC Systems Biology.
[3] Francisco Salavert,et al. Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity , 2015, Scientific Reports.
[4] Susumu Goto,et al. Data, information, knowledge and principle: back to metabolism in KEGG , 2013, Nucleic Acids Res..
[5] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.
[6] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[7] M. Warmuth,et al. Targeted Cancer Therapies in the Twenty‐First Century: Lessons From Imatinib , 2010, Clinical pharmacology and therapeutics.
[8] Rosa D. Hernansaiz-Ballesteros,et al. Babelomics 5.0: functional interpretation for new generations of genomic data , 2015, Nucleic Acids Res..
[9] Rosa D. Hernansaiz-Ballesteros,et al. Assessing the impact of mutations found in next generation sequencing data over human signaling pathways , 2015, Nucleic Acids Res..
[10] Francisco Salavert,et al. Inferring the functional effect of gene expression changes in signaling pathways , 2013, Nucleic Acids Res..
[11] Marta Bleda,et al. CellBase, a comprehensive collection of RESTful web services for retrieving relevant biological information from heterogeneous sources , 2012, Nucleic Acids Res..
[12] S. Wilhelm,et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.
[13] Walter Kolch,et al. Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients , 2015, Science Signaling.
[14] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.